651
A 62-year-old woman who was being treated for squamous cell carcinoma of the head and neck developed a chemotherapy-related hemolytic-uremic syndrome during the second cycle of neoadjuvant chemotherapy consisting of cisplatin, bleomycin, and methotrexate.
 A 62-year-old woman who was being treated for squamous cell carcinoma of the head and neck: Subject; 62-year-old: Subject.Age; woman: Subject.Gender; a chemotherapy-related hemolytic-uremic syndrome: Effect; the second cycle of neoadjuvant chemotherapy consisting of cisplatin, bleomycin, and methotrexate: Treatment; squamous cell carcinoma of the head and neck: Treatment.Disorder; second cycle: Treatment.Dosage; cisplatin: Treatment.Drug; bleomycin: Treatment.Drug; methotrexate: Treatment.Drug; cisplatin: Combination.Drug; bleomycin: Combination.Drug; methotrexate: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 A 62-year-old woman who was being treated for squamous cell carcinoma of the head and neck: Subject; 62-year-old: Subject.Age; woman: Subject.Gender; a chemotherapy-related hemolytic-uremic syndrome: Effect; the second cycle of neoadjuvant chemotherapy consisting of cisplatin, bleomycin, and methotrexate: Treatment; squamous cell carcinoma of the head and neck: Treatment.Disorder; second cycle: Treatment.Dosage; cisplatin: Treatment.Drug; bleomycin: Treatment.Drug; methotrexate: Treatment.Drug; cisplatin: Combination.Drug; bleomycin: Combination.Drug; methotrexate: Combination.Drug